PHARMACY

Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment

BY Alaric DeArment

SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

The company conducted a study comparing the cost-effectiveness of LAIA, insulin lispro mix 75/25 and insulin lispro mix 50/50 in patients with Type 2 diabetes. Lilly sells insulin lispro under the brand name Humalog.

Analysis of the study found that for patients who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be more cost-effective than LAIA in the long-term treatment of the disease.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA accepts regulatory filing for Prochieve

BY Alaric DeArment

LIVINGSTON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug designed to prevent premature birth in pregnant women.

Columbia Labs and Watson Pharmaceuticals announced Monday that the FDA would review their application for Prochieve (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the third trimester of pregnancy.

“We are pleased to achieve this important regulatory milestone and look forward to working with the FDA as they review the data package for the Prochieve new drug application,” Columbia president and CEO Frank Condella said.

Under a collaborative agreement between Watson and Columbia, Watson will make a $5 million milestone payment to Columbia.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Adding Byetta to diabetes regimen could cut heart failure risk

BY Alaric DeArment

SAN DIEGO — Use of a drug for Type 2 diabetes made by Eli Lilly and Amylin Pharmaceuticals may lower patients’ risk of heart failure, according to a new study.

The study of more than 778,000 patients taking the injected drug Byetta (exenatide) found that adding the drug to a pre-existing diabetes regimen, especially if that regimen included insulin, was associated with reduced likelihood of heart failure. Results were presented Saturday at the 71st Scientific Sessions of the American Diabetes Association in San Diego.

The companies also are conducting another study for Bydureon, a long-acting formulation of Byetta. The study, called “EXSCEL,” began last year and will include about 9,500 patients with results expected as early as 2016. The study is designed to determine if Bydureon has favorable cardiovascular effects compared with traditional diabetes medications.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?